InvestorsHub Logo
Followers 54
Posts 3385
Boards Moderated 0
Alias Born 10/26/2013

Re: drcs post# 592533

Thursday, 05/11/2023 8:19:52 PM

Thursday, May 11, 2023 8:19:52 PM

Post# of 694279
You can call me Long, you can call me Very Long, but you doesn’t haveta call me Cheerleader.
Everybody who is invested here understands there were difficulties w the trial because of PsPD and crossover so that the SAP was very careful in the selection of external controls, Some excerpts

The design of this SAP has been developed by multiple independent experts, and reviewed by independent, leading neuro-oncology experts who were not involved in the Trial, and all of the analyses called for under this SAP will be carried out by independent experts. This SAP was developed prior to data lock and unblinding of the Trial data…
… The identification of the most appropriate external controls from other clinical trials in newly diagnosed GBM, based upon comparable patient populations, time period of trial conducted, extent of resection and standard of care RT/TMZ treatments consists of a structured literature search and has been conducted by the independent expert firm, York Health Economics Consortium, UK (see Appendix A). This independent expert analysis was checked and confirmed with a panel of leading, neuro-oncology experts who were not involved in the Trial. In addition, the statistical analyses include methodologies to ensure appropriate matching of these identified external controls to the DCVax®-L trial population based on known prognostic factors, applied by independent statisticians. To support the first secondary endpoint for survival analysis in recurrent GBM, a systematic literature search was also conducted similarly, to identify the most appropriate external controls from clinical trials in recurrent GBM, based upon comparable patient populations and the time period of the trial conducted (see Appendix B).

The icing on the cake is that it’s safe but I can’t wait till they provide top line Secondary Endpoint #2 which is

Confirmed Progression Free Survival (cPFS) - Comparison between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.

That would seal the deal for me. But I guess one of the reasons for the weak stock price is that is not a certainty for all of us.

(Aside – I was thinking of the comedian, Bill Saluga, who passed away a month or so ago, regarding my initial wordology. Here’s one of his skits w Redd Foxx.)
https://www.google.com/search?q=you+can+call+me+ray+gif&biw=1326&bih=692&sxsrf=APwXEddDQX4scH0u1Hz0xKNq7NV3vcKhHA%3A1683844174264&ei=TmxdZOC0D5yt5NoP2JOn0Ak&oq=you+can+call+me+ray+meme&gs_lcp=Cgxnd3Mtd2l6LXNlcnAQARgCMgoIABBHENYEELADMgoIABBHENYEELADMgoIABBHENYEELADMgoIABBHENYEELADMgoIABBHENYEELADMgoIABBHENYEELADMgoIABBHENYEELADMgoIABBHENYEELADSgQIQRgAUABYAGCwPGgCcAB4AIABAIgBAJIBAJgBAMgBCMABAQ&sclient=gws-wiz-serp#fpstate=ive&vld=cid:abdadd18,vid:ZCqh5ROtQRg
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News